Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity

Molecular Psychiatry

Volumn 7, Issue 7, 2002, Pages 726-733

  Farber, N B ^a   Jiang, X P ^a   Heinkel, C ^a   Nemmers, B ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Anticonvulsants; Bipolar disorder; Dissociative anesthetics; MK 801; Neurodegeneration; Psychosis; Rats; Retrosplenial cortex; Schizophrenia; Voltage gated Na+ channel inhibitors

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIZOCILPINE; ETHOSUXIMIDE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENYTOIN; RILUZOLE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; TETRODOTOXIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; MANIC DEPRESSIVE PSYCHOSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; DIZOCILPINE MALEATE; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; ION CHANNEL GATING; NEUROTRANSMITTER AGENTS; PHENYTOIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SODIUM CHANNELS; TRIAZINES; VALPROIC ACID;

EID: 0036366102     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001087     Document Type: Article

References (56)

1. Abnormal mental states induced by phencyclidine as a model of schizophrenia
2. Recent advances in the phencyclidine model of schizophrenia
3. Glutamate receptor dysfunction and schizophrenia
4. The role of NMDA receptor hypofunction in idiopathic psychotic disorders
5. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine
6. Loss of NMDA, but not GABA-A, binding in the brains of aged rats and monkeys
7. Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain
8. Excitotoxic neurodegeneration in Alzheimer disease; new hypothesis and new therapeutic strategies
9. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
10. Structural organization of cingulate cortex: Areas, neurons, and somatodendritic transmiter receptors
11. Phencyclidlne, dizocilpine, and cerebrocortical neurons
12. NMDA antagonist neurotoxicity: Mechanism and prevention
13. Dissimilar patterns of degeneration in brain following four different addictive stimulants
14. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine
15. MK-801-induced neuronal damage in rats
16. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity
17. Muscimol prevents NMDA antagonist neurotoxicity by acting at GABAergic receptors in the diagonal band and anterior thalamus
18. Cellular effects of antiepileptic drugs
19. Selective depression of low-release probability excitatory synapses by sodium channel blockers
20. Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons
21. + channels as targets for neuroprotective drugs
22. Blockage of sodium conductance increase in lobster giant axon by tarichatoxin (tetrodotoxin)
23. Basis of tetrodotoxin's selectivity in blockage of squid axons
24. Mechanism of action of new antiepileptic drugs
25. Isoflurane and propofol block neurotoxicity caused by MK-801 in the rat posterior cingulate/retrosplenial cortex
26. Comparitive anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats
27. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid transmission - I anticonvulsant properties
28. Electrophysiological actions of felbamate on rat striatal neurones
29. + channels from human and rat brain
30. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors
31. Mechanism of action of the anticonvulsant felbamate: Opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors
32. The pharmacology of SDZ EAA 494, a competitive NMDA antagonist
33. The competitive NMDA antagonist, D-CPP-ene, potentiates the anticonvulsant activity of conventional antiepileptics against maximal electroshock-induced seizures in mice
34. Influence of MK-801 on the anticonvulsant activity of antiepileptics
35. Pharmacological characterization of LY233053: A structurally novel tetrazolesubstituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action
36. Gabapentin
37. Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex
38. Glycine agonists: What can they teach us about schizophrenia?
39. Antiglutamatergic therapy in Alzheimer's disease - Effects of lamotrigine
40. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression
41. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder
42. Lamotrigine and clozapine for bipolar disorder
43. Carbamazepine versus lithium in mania: A double-blind study
44. Carbamazepine compared with lithium in the treatment of mania
45. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified
46. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder
47. Valproate in the treatment of acute mania. A placebo-controlled study
48. Efficacy of divalproex vs lithium and placebo in the treatment of mania
49. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder
50. Phenytoin as an antimanic anticonvulsant: A controlled study
51. Gabapentin in the acute treatment of refractory bipolar disorder
52. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy
53. Gabapentin treatment of the non-refractory bipolar spectrum: An open case series
54. Lamotrigine
55. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action